Maxigen Biotech (1783) Stock Overview
Researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
1783 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Maxigen Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$38.70 |
| 52 Week High | NT$48.85 |
| 52 Week Low | NT$37.80 |
| Beta | 0.17 |
| 1 Month Change | -0.13% |
| 3 Month Change | -10.62% |
| 1 Year Change | -16.05% |
| 3 Year Change | -29.45% |
| 5 Year Change | 30.13% |
| Change since IPO | -11.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1783 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -2.8% | 5.3% | -7.1% |
| 1Y | -16.1% | 35.0% | 90.9% |
Return vs Industry: 1783 underperformed the TW Biotechs industry which returned 35% over the past year.
Return vs Market: 1783 underperformed the TW Market which returned 90.9% over the past year.
Price Volatility
| 1783 volatility | |
|---|---|
| 1783 Average Weekly Movement | 3.0% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in TW Market | 12.2% |
| 10% least volatile stocks in TW Market | 2.6% |
Stable Share Price: 1783 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1783's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Ching-Ting Chen | mbi-bio.com |
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, electronic instructions for use, and medical aesthetics, as well as engages in collagen purification activities.
Maxigen Biotech Inc. Fundamentals Summary
| 1783 fundamental statistics | |
|---|---|
| Market cap | NT$3.49b |
| Earnings (TTM) | NT$271.02m |
| Revenue (TTM) | NT$825.25m |
Is 1783 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1783 income statement (TTM) | |
|---|---|
| Revenue | NT$825.25m |
| Cost of Revenue | NT$252.21m |
| Gross Profit | NT$573.04m |
| Other Expenses | NT$302.03m |
| Earnings | NT$271.02m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.02 |
| Gross Margin | 69.44% |
| Net Profit Margin | 32.84% |
| Debt/Equity Ratio | 6.1% |
How did 1783 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/11 12:49 |
| End of Day Share Price | 2026/06/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Maxigen Biotech Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Regina Lee | Capital Securities Corporation |
| Hsiu Chi Lin | Masterlink Securities Investment Advisory |